BioCryst Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.07 Insider Own0.90% Shs Outstand184.90M Perf Week4.03%
Market Cap1.86B Forward P/E- EPS next Y-0.78 Insider Trans-19.60% Shs Float183.87M Perf Month13.64%
Income-194.00M PEG- EPS next Q-0.34 Inst Own71.60% Short Float16.07% Perf Quarter-35.64%
Sales188.00M P/S9.87 EPS this Y6.00% Inst Trans8.19% Short Ratio6.01 Perf Half Y-22.77%
Book/sh-0.89 P/B- EPS next Y40.00% ROA-46.80% Target Price17.45 Perf Year-33.08%
Cash/sh2.53 P/C4.19 EPS next 5Y15.20% ROE148.00% 52W Range7.61 - 19.99 Perf YTD-23.61%
Dividend- P/FCF- EPS past 5Y-6.60% ROI-25.90% 52W High-45.77% Beta2.32
Dividend %- Quick Ratio6.10 Sales past 5Y42.90% Gross Margin99.10% 52W Low42.44% ATR0.60
Employees358 Current Ratio6.30 Sales Q/Q161.30% Oper. Margin-64.00% RSI (14)58.35 Volatility5.62% 6.21%
OptionableYes Debt/Eq- EPS Q/Q-10.70% Profit Margin- Rel Volume0.51 Prev Close10.58
ShortableYes LT Debt/Eq- EarningsMay 05 BMO Payout- Avg Volume4.92M Price10.84
Recom2.30 SMA207.21% SMA5013.42% SMA200-18.55% Volume2,519,983 Change2.46%
Apr-18-22Downgrade Barclays Overweight → Equal Weight $22 → $13
Apr-11-22Downgrade BofA Securities Buy → Neutral $21 → $14
Dec-10-21Initiated Oppenheimer Outperform $16
Aug-06-21Downgrade Jefferies Buy → Hold
Aug-03-21Initiated Cantor Fitzgerald Overweight $21
Mar-01-21Initiated Cowen Outperform $16
Sep-29-20Resumed JP Morgan Overweight $7
Jun-17-20Initiated BTIG Research Neutral
May-05-20Upgrade Barclays Equal Weight → Overweight $7
Nov-15-19Upgrade BofA/Merrill Neutral → Buy $5 → $4
May-24-19Downgrade RBC Capital Mkts Outperform → Sector Perform $16 → $4.50
Nov-16-18Resumed Piper Jaffray Overweight $15
Aug-08-18Resumed JP Morgan Overweight $9
Jul-17-18Upgrade BofA/Merrill Underperform → Neutral
Jun-22-18Initiated Seaport Global Securities Neutral
Jan-02-18Upgrade RBC Capital Mkts Sector Perform → Outperform
Dec-20-17Initiated Barclays Equal Weight $6
Sep-15-17Initiated RBC Capital Mkts Sector Perform $6
Sep-06-17Upgrade JP Morgan Neutral → Overweight
Sep-06-17Upgrade Jefferies Hold → Buy
Jul-01-22 07:00AM  
Jun-28-22 11:52AM  
Jun-23-22 07:00AM  
Jun-22-22 07:00AM  
Jun-20-22 08:26AM  
Jun-10-22 02:09PM  
Jun-09-22 07:00AM  
Jun-08-22 05:33PM  
Jun-07-22 09:00AM  
Jun-06-22 07:00AM  
Jun-01-22 07:00AM  
May-19-22 06:00PM  
May-06-22 04:11PM  
May-05-22 06:10PM  
May-04-22 04:15PM  
Apr-28-22 03:02PM  
Apr-27-22 07:35PM  
Apr-21-22 07:00AM  
Apr-20-22 09:17AM  
Apr-19-22 10:30AM  
Apr-18-22 05:40PM  
Apr-14-22 05:35AM  
Apr-13-22 05:14PM  
Apr-11-22 08:33AM  
Apr-08-22 02:55PM  
Apr-05-22 07:15AM  
Mar-23-22 02:03PM  
Mar-15-22 11:20AM  
Mar-03-22 07:00AM  
Mar-02-22 07:00AM  
Feb-24-22 07:00AM  
Feb-23-22 06:30PM  
Feb-22-22 07:00AM  
Feb-09-22 07:00AM  
Feb-08-22 07:00AM  
Feb-03-22 07:00AM  
Feb-01-22 01:38PM  
Jan-24-22 01:37PM  
Jan-19-22 04:30AM  
Jan-14-22 04:31AM  
Jan-13-22 04:20PM  
Jan-11-22 01:48PM  
Jan-10-22 01:37PM  
Jan-07-22 09:25AM  
Jan-04-22 04:15PM  
Dec-15-21 08:45AM  
Dec-08-21 06:38PM  
Dec-07-21 04:38PM  
Dec-03-21 07:00AM  
Nov-30-21 11:18AM  
Nov-29-21 10:00AM  
Nov-23-21 07:21AM  
Nov-22-21 07:10AM  
Nov-12-21 07:00AM  
Nov-05-21 07:00AM  
Nov-03-21 02:31PM  
Nov-02-21 07:00AM  
Nov-01-21 07:00AM  
Oct-27-21 03:04PM  
Oct-26-21 07:00AM  
Oct-25-21 05:23PM  
Oct-20-21 07:00AM  
Oct-13-21 10:00AM  
Oct-04-21 07:00AM  
Sep-30-21 06:17AM  
Sep-21-21 07:00AM  
Sep-20-21 07:00AM  
Sep-16-21 11:50AM  
Sep-15-21 08:20PM  
Sep-09-21 07:00AM  
Sep-03-21 07:00AM  
Sep-02-21 04:01PM  
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ABERCROMBIE GEORGE BDirectorApr 18Option Exercise3.325,00016,6005,000Apr 20 04:23 PM
ABERCROMBIE GEORGE BDirectorApr 18Sale11.045,00055,2000Apr 20 04:23 PM
Thackray Helen M.Chief R&D OfficerApr 01Sale16.207,600123,120136,400Apr 04 04:32 PM
Sheridan William PChief Medical OfficerMar 10Option Exercise3.22148,302477,532199,093Mar 14 04:21 PM
Sheridan William PChief Medical OfficerMar 10Sale16.88161,1392,719,49337,954Mar 14 04:21 PM
Babu Yarlagadda SChief Discovery OfficerMar 07Sale17.1620,000343,200230,056Mar 09 04:24 PM
Jones Michael LExec. Director, Finance - PAOMar 01Option Exercise4.732,30010,87913,498Mar 03 05:04 PM
Jones Michael LExec. Director, Finance - PAOMar 01Sale17.202,30039,56011,198Mar 03 05:04 PM
ABERCROMBIE GEORGE BDirectorFeb 15Option Exercise3.325,00016,6005,000Feb 16 04:25 PM
ABERCROMBIE GEORGE BDirectorFeb 15Sale18.505,00092,5000Feb 16 04:25 PM
Stonehouse Jon PPresident & CEOJan 11Option Exercise4.73184,000870,3201,085,602Jan 13 04:45 PM
Stonehouse Jon PPresident & CEOJan 11Sale15.04184,0002,767,360901,602Jan 13 04:45 PM
Babu Yarlagadda SChief Discovery OfficerDec 07Option Exercise4.7362,000293,260245,156Dec 09 04:38 PM
Babu Yarlagadda SChief Discovery OfficerDec 07Sale12.2030,100367,220215,056Dec 09 04:38 PM
MILANO VINCENTDirectorNov 24Buy12.197,50091,42517,500Nov 24 06:35 PM
Doyle AnthonyChief Financial OfficerNov 23Buy12.4835,258440,02093,719Nov 24 06:35 PM
ABERCROMBIE GEORGE BDirectorNov 15Option Exercise3.325,00016,6005,000Nov 17 04:27 PM
ABERCROMBIE GEORGE BDirectorNov 15Sale12.275,00061,3500Nov 17 04:27 PM
Hutson Nancy JDirectorOct 15Option Exercise3.46105,000363,450170,073Oct 19 04:21 PM
Hutson Nancy JDirectorOct 15Sale15.40105,0001,617,00065,073Oct 19 04:21 PM
ABERCROMBIE GEORGE BDirectorSep 15Option Exercise2.635,00013,1505,000Sep 17 04:31 PM
ABERCROMBIE GEORGE BDirectorSep 15Sale15.065,00075,3000Sep 17 04:31 PM
LEE KENNETH B JRDirectorSep 13Option Exercise3.2215,00048,30030,252Sep 15 04:26 PM
LEE KENNETH B JRDirectorSep 13Sale15.356,00092,10024,252Sep 15 04:26 PM
ABERCROMBIE GEORGE BDirectorSep 10Option Exercise2.8671,000202,71074,000Sep 14 04:14 PM
ABERCROMBIE GEORGE BDirectorSep 10Sale15.0974,0001,116,6600Sep 14 04:14 PM
ABERCROMBIE GEORGE BDirectorJul 15Option Exercise2.635,00013,1508,000Jul 19 04:39 PM
ABERCROMBIE GEORGE BDirectorJul 15Sale15.695,00078,4503,000Jul 19 04:39 PM